Pediatrix Medical Group (MD) Expected to Release Earnings on Thursday

Pediatrix Medical Group (NYSE:MD) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Pediatrix Medical Group to post earnings of $0.65 per share and revenue of $498.18 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%. Pediatrix Medical Group’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.53 EPS. On average, analysts expect Pediatrix Medical Group to post $2.17 EPS for the current fiscal year and $2.23 EPS for the next fiscal year.

Pediatrix Medical Group Trading Down 0.0%

MD opened at $28.07 on Thursday. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of 13.43 and a beta of 0.61. Pediatrix Medical Group has a one year low of $16.82 and a one year high of $28.29. The business has a 50 day simple moving average of $26.55 and a two-hundred day simple moving average of $24.86. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.32 and a quick ratio of 1.32.

Analyst Ratings Changes

MD has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. UBS Group lifted their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 13th. Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price objective for the company from $27.00 to $28.00 in a research report on Wednesday, August 19th. Finally, Weiss Ratings upgraded shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $26.60.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.